• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺炎链球菌和流感嗜血杆菌对奎奴普丁/达福普汀(RP59500)药敏试验的临时质量控制参数及解释标准。抗菌药物检测质量控制组。

Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group.

作者信息

Fuchs P, Barry A, Brown S

机构信息

The Clinical Microbiology Institute, Wilsonville, Oregon 97070, USA.

出版信息

Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):197-201. doi: 10.1007/BF01691118.

DOI:10.1007/BF01691118
PMID:9665303
Abstract

Studies were undertaken to select tentative criteria for susceptibility testing of quinupristin/dalfopristin against Streptococcus pneumoniae and Haemophilus influenzae. Against 612 isolates of Streptococcus pneumoniae, MICs of quinupristin/dalfopristin were < or = 1.0 microg/ml for all but one strain. With a tentative MIC breakpoint of either < or = 1.0 microg/ml or < or = 2.0 microg/ml for susceptible, a disk diffusion zone diameter breakpoint of > or = 19 mm embraced all but two of the susceptible pneumococci; > or = 16 mm included all strains. For Haemophilus influenzae, MICs of quinupristin/dalfopristin clustered near the tentative breakpoints; 91.5% of the MICs were 2.0 to 8.0 microg/ml. This precluded satisfactory performance of the disk diffusion test in discriminating between resistant and susceptible isolates unless MIC breakpoints are modified for this species: clinical experience will be needed before that can be justified. Based on data from a multilaboratory study, the following quality control limits are proposed for Streptococcus pneumoniae ATCC 49619 when testing quinupristin/dalfopristin: 0.25 to 1.0 microg/ml for broth microdilution tests and 19 to 24 mm for disk diffusion tests. For tests of Haemophilus influenzae ATCC 29247, MIC limits are 2.0 to 16 microg/ml; disk tests were very reproducible but are not yet recommended.

摘要

开展了多项研究,以选择用于检测奎奴普丁/达福普汀对肺炎链球菌和流感嗜血杆菌敏感性的初步标准。对于612株肺炎链球菌分离株,除一株外,奎奴普丁/达福普汀的最低抑菌浓度(MIC)均≤1.0μg/ml。对于敏感菌,暂定的MIC界值为≤1.0μg/ml或≤2.0μg/ml,纸片扩散法抑菌圈直径界值≥19mm涵盖了除两株外的所有敏感肺炎球菌;≥16mm则涵盖了所有菌株。对于流感嗜血杆菌,奎奴普丁/达福普汀的MIC集中在暂定界值附近;91.5%的MIC为2.0至8.0μg/ml。这使得纸片扩散试验在区分耐药和敏感分离株时表现不佳,除非针对该菌种修改MIC界值:在此之前需要临床经验来证明其合理性。基于一项多实验室研究的数据,在检测奎奴普丁/达福普汀时,针对肺炎链球菌ATCC 49619提出以下质量控制限度:肉汤微量稀释试验为0.25至1.0μg/ml,纸片扩散试验为19至24mm。对于流感嗜血杆菌ATCC 29247的检测,MIC限度为2.0至16μg/ml;纸片试验重复性很好,但目前尚不推荐使用。

相似文献

1
Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group.肺炎链球菌和流感嗜血杆菌对奎奴普丁/达福普汀(RP59500)药敏试验的临时质量控制参数及解释标准。抗菌药物检测质量控制组。
Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):197-201. doi: 10.1007/BF01691118.
2
Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.肺炎链球菌和流感嗜血杆菌对头孢妥仑的敏感性及临时解释标准。
Diagn Microbiol Infect Dis. 2000 Aug;37(4):265-9. doi: 10.1016/s0732-8893(00)00160-7.
3
Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
J Antimicrob Chemother. 1997 May;39 Suppl A:81-5. doi: 10.1093/jac/39.suppl_1.81.
4
Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.奎奴普丁/达福普汀药敏试验的临时解释标准。
J Antimicrob Chemother. 1997 May;39 Suppl A:87-92. doi: 10.1093/jac/39.suppl_1.87.
5
Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group.流感嗜血杆菌和肺炎链球菌对甲氧苄啶及甲氧苄啶-磺胺甲恶唑敏感性检测的解释标准和质量控制参数。抗菌药物敏感性检测OC组。
J Clin Microbiol. 1997 Jan;35(1):125-31. doi: 10.1128/jcm.35.1.125-131.1997.
6
Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae.奎奴普丁/达福普汀及其成分对流感嗜血杆菌的活性。
J Antimicrob Chemother. 1997 May;39 Suppl A:69-73. doi: 10.1093/jac/39.suppl_1.69.
7
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.加替沙星对流感嗜血杆菌和卡他莫拉菌的活性,包括药敏试验的建立、E试验比较以及流感嗜血杆菌的质量控制指南。
J Clin Microbiol. 1999 Jun;37(6):1999-2002. doi: 10.1128/JCM.37.6.1999-2002.1999.
8
A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae.新型口服链阳菌素XRP 2868与奎奴普丁-达福普汀治疗流感嗜血杆菌、金黄色葡萄球菌和肺炎链球菌耐药菌株的比较。
Curr Microbiol. 2005 Dec;51(6):363-6. doi: 10.1007/s00284-005-0027-9. Epub 2005 Oct 25.
9
In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.奎奴普丁/达福普汀在台湾对革兰氏阳性菌流感嗜血杆菌和卡他莫拉菌的体外活性
Zhonghua Yi Xue Za Zhi (Taipei). 2000 Jun;63(6):433-9.
10
In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.头孢妥仑及其他抗菌药物对西班牙萨拉戈萨分离出的288株肺炎链球菌和220株流感嗜血杆菌临床菌株的体外活性。
Diagn Microbiol Infect Dis. 2008 Oct;62(2):210-5. doi: 10.1016/j.diagmicrobio.2008.06.007. Epub 2008 Aug 20.

引用本文的文献

1
Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.新型口服链阳菌素XRP 2868与其他药物相比,对肺炎链球菌和嗜血杆菌属的活性。
Antimicrob Agents Chemother. 2003 Oct;47(10):3270-4. doi: 10.1128/AAC.47.10.3270-3274.2003.
2
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀:用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.

本文引用的文献

1
Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.奎奴普丁/达福普汀药敏试验的临时解释标准。
J Antimicrob Chemother. 1997 May;39 Suppl A:87-92. doi: 10.1093/jac/39.suppl_1.87.
2
Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.奎奴普丁/达福普汀:抗菌谱、药代动力学及初步临床经验
Microb Drug Resist. 1995 Fall;1(3):223-34. doi: 10.1089/mdr.1995.1.223.
3
RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci.
RP 59500,一种对北美葡萄球菌近期分离株具有高度活性的新型链阳性菌素。
Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):223-6. doi: 10.1016/0732-8893(93)90113-l.
4
In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.一种链阳性菌素(RP59500)、三种大环内酯类药物及一种氮杂内酯类药物对四种呼吸道病原体的体外活性。
Antimicrob Agents Chemother. 1995 Jan;39(1):238-40. doi: 10.1128/AAC.39.1.238.
5
In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.
Diagn Microbiol Infect Dis. 1995 Mar;21(3):169-73. doi: 10.1016/0732-8893(95)00068-l.
6
In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.半合成注射用普那霉素RP 59500对葡萄球菌、链球菌和肠球菌的体外活性
Antimicrob Agents Chemother. 1991 Mar;35(3):553-9. doi: 10.1128/AAC.35.3.553.
7
In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500.
J Antimicrob Chemother. 1992 Jul;30 Suppl A:95-9. doi: 10.1093/jac/30.suppl_a.95.
8
The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination.新型链阳菌素RP 59500、RP 57669和RP 54476单独及联合使用时的体外活性。
J Antimicrob Chemother. 1992 Jul;30 Suppl A:83-94. doi: 10.1093/jac/30.suppl_a.83.